Better Options for Chronic Cancer Pain

NCT06574009

Status	RECRUITING
Phase	Phase 4
Sponsor	VA Office of Research and Development
Enrollment	294 participants

Key Eligibility Criteria

Inclusion (6)

- Veterans must have had a qualifying solid tumor (bladder, breast, colorectal, head and neck, liver, lung, pancreas, prostate, or urinary tract) without evidence of active disease for at least 6 months
- Participants must be 6 months away from their last receipt of cytotoxic, radiation, or surgical cancer treatments but can be on hormonal or biologic therapies needed to sustain remission or cancer control.
- Participants must report pain \>=4 (on 0-10 NRS) on their last 3 recordings in the electronic medical record. Veterans should be on Long Term Opioid Therapy (LTOT) defined as:
- a qualifying opioid analgesic dispensed within the prior 30 days
- plus 150 days' supply of a qualifying opioid (fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone) in the 180 days before the most recent dispensing date with no between-fill gaps \>40 days

... and 1 more (see full listing online)

Exclusion (10)

- Veterans with total daily opioid doses \>= 300 Morphine Milligram Equivalents (MME) will be excluded (higher doses require tapering prior to rotation to buprenorphine, which is something the investigators do not want to examine in this study)
- Veterans with referrals or visits to a substance abuse clinic within the prior 2 years will be excluded to avoid including individuals requiring addiction expertise that is not available one the multidisciplinary pain teams
- The investigators will also exclude Veterans with:
- current or past use of buprenorphine
- active alcohol use disorder or substance use

... and 5 more (see full listing online)

Locations (2 total)

Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis, Indiana, United States
VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States